Solid Biosciences Inc. (SLDB), a life sciences firm, announced on Tuesday that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for SGT-212. This innovative gene therapy aims to treat Friedreich's ataxia (FA), a progressive disease resulting from deficient levels of the frataxin protein.
SGT-212, an AAV-based gene therapy candidate, is engineered to deliver full-length frataxin through both systemic intravenous (IV) infusion and direct intradentate nuclei (IDN) infusion into the cerebellum. This approach targets the neurological and systemic clinical symptoms of FA, aiming to manage the full range of disease progression.
In the latter half of 2025, Solid Biosciences plans to launch a first-in-human, open-label, dose-finding Phase 1b clinical trial. This study will include both non-ambulatory and ambulatory adult patients with FA, divided into up to three cohorts. It will assess the safety and tolerability of simultaneous systemic and bilateral IDN administration of SGT-212. Participants will be monitored for up to five years post-treatment.
The material has been provided by InstaForex Company - www.instaforex.com
SGT-212, an AAV-based gene therapy candidate, is engineered to deliver full-length frataxin through both systemic intravenous (IV) infusion and direct intradentate nuclei (IDN) infusion into the cerebellum. This approach targets the neurological and systemic clinical symptoms of FA, aiming to manage the full range of disease progression.
In the latter half of 2025, Solid Biosciences plans to launch a first-in-human, open-label, dose-finding Phase 1b clinical trial. This study will include both non-ambulatory and ambulatory adult patients with FA, divided into up to three cohorts. It will assess the safety and tolerability of simultaneous systemic and bilateral IDN administration of SGT-212. Participants will be monitored for up to five years post-treatment.
The material has been provided by InstaForex Company - www.instaforex.com